BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
BioSyntech specialized in the development, manufacturing and commercialization of biotherapeutic thermogels for regenerative medicine (tissue repair) and therapeutic delivery. The company’s assets were acquired in 2010 by Piramal Healthcare Ltd.
BioSyntech
Laval, Quebec
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.